JPMorgan Reinstates BeOne Medicines (ONC) at Overweight
Tweet
Share
E-mailGet Alerts ONC Hot Sheet
Price: $347.48 -2.4%
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
JPMorgan analyst Jessica Fye reinstates coverage on BeOne Medicines (NASDAQ: ONC) with a Overweight rating and a price target of $415.00.
For an analyst ratings summary and ratings history on BeOne Medicines click here. For more ratings news on BeOne Medicines click here.
Shares of BeOne Medicines closed at $297.01 yesterday.
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- Alliance Global Partners Starts Momentus (MNTS) at Buy
- BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
